GLP-1 agonists demonstrate benefits such as reduced mortality, brain protection, and slowed kidney aging, positioning them as potential longevity drugs in humans.

“Because if you apply them to people with type two diabetes and significant obesity and you correct the metabolic dysfunction you're going to live longer. So by that regard it's a geroprotective agent.”

“But there is now this sort of growing budding interest amongst you know many people about this potential GLP1 agonist being a longevity drug because of these different you know outcome studies that have been observational in nature right you're looking at correlation here.”